IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,082,854 shares of the medical research company’s stock after selling 43,747 shares during the quarter. Bank of New York Mellon Corp’s holdings in IQVIA were worth $212,792,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of IQV. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth $1,616,000. Simplify Asset Management Inc. increased its stake in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after acquiring an additional 3,894 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new position in shares of IQVIA in the 4th quarter valued at about $941,000. Finally, Fifth Third Bancorp grew its holdings in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Down 2.4 %

NYSE IQV opened at $186.40 on Friday. The company’s fifty day moving average price is $199.30 and its two-hundred day moving average price is $215.26. The company has a market capitalization of $32.82 billion, a price-to-earnings ratio of 24.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 12 month low of $184.66 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on IQV. Bank of America cut their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Robert W. Baird reduced their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.